Searched for
NPPA CANCER DRUG PRICE CAP
NPPA caps trade margins on 137 cancer drugs at 30%, revised prices from Nov 9India's National Pharmaceutical Pricing Authority has capped trade margins for 137 anti-cancer drugs at 30% of their maximum retail price. ...- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
- Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...
- Protect patients and patents smartlyThe Kerala High Court has stressed the importance of making cancer medicines like ribociclib more affordable for patients. The Government o...
- Pope Leo cancer diagnosis: What is lung adenocarcinoma, symptoms, treatments & who are at riskPope Leo has been found to have lung adenocarcinoma, which is among the most common types of lung cancer. He recently had surgery to excise...
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts applicationZydus Lifesciences has received acceptance for its application regarding the biosimilar of Keytruda, which is a major cancer drug. The USFD...
- Panel to finalise cancer drugs for 30% trade margin cap; Rs 2,500 crore annual savings possibleAn expert group is finalizing the list of cancer medicines for a new trade margin cap. The government plans to implement a 30% cap to reduc...
- SC asks govt to broaden inflated pricing review beyond oncologyThe Supreme Court has asked the government to address high markups on medicines and medical devices. The court questioned the decision to l...
- Ministry of Science signs MoU with Peptris for collab in AI-based drug discovery and developmentThe Ministry of Science has entered into a partnership with Peptris Technologies to bolster drug development under the initiative called VI...
- Supreme Court questions govt over drug pricing, asks why cap limited to anti-cancer medicinesThe Supreme Court expressed its worry over the government's restriction of price control measures to only anti-cancer drugs, questioning wh...
- Apollo, Max Health, other hospital stocks rally up to 5% despite cancer drug price caps. Why Jefferies stays bullishHospital stocks rose up to 5% after the government capped trade margins on non-scheduled anti-cancer drugs at 30%, potentially reducing med...
- Cancer drugs may get up to 70% cheaper as govt fixes trade margins on non-scheduled medicines at 30%The government is aiming to cap trade margins on anti-cancer medications at 30%. An expert committee has been tasked with compiling a repor...
- Form panel to curb pharma freebies: SCThe Supreme Court has ordered the government to establish a committee to investigate unethical pharmaceutical marketing. The committee is t...
- National Medical Commission bans doctors & hospitals from using AI-generated patient testimonials, fake cure claims in medical adsThe National Medical Commission has implemented new ethical advertising guidelines affecting doctors and hospitals. These guidelines prohib...
- Govt set to cap trade margins on more cancer drugs before SC hearingThe Indian government plans to announce a new list of cancer drugs for trade margin rationalisation today. Union Health Minister JP Nadda w...
- Supreme Court seeks committee to curb pharma firms’ unethical marketing practicesThe Supreme Court has directed the government to form a committee regarding pharmaceutical marketing regulations. This follows concerns ove...
- Hospital pricing part of wider value chain: Max MDAbhay Soi, chairman of Max Healthcare, commented on scrutiny regarding hospital pricing in India. He stated that hospitals should be evalua...
- Karnataka flags 52x mark-up on cancer drugs, seeks Centre's interventionKarnataka conducted inspections revealing significant price disparities between hospital procurement and patient billing for cancer drugs a...
- Fortis, Apollo, other hospital stocks slump up to 10% in 2 days after SC questions steep markups. Buying opportunity?Hospital stocks extended losses for a second session after the Supreme Court questioned steep markups on cancer drugs and raised concerns o...
- Cancer drug costs Rs 2,700, sells for Rs 27,000: SC questions 10x markup at hospitalsThe Supreme Court has questioned steep markups on cancer drugs and asked the Centre to examine a uniform 16% margin on all medicines. The c...
Load More
